27P Treatment outcomes and toxicity profiles in South Asian patients of high-risk endometrial cancer treated with PORTEC-3 trial regimen

While endometrial cancers are associated with favourable outcomes due to early symptomatic evaluation, patients high-risk features at a higher risk of recurrence. Although results PORTEC-3 trial established the role concurrent chemoradiation followed by adjuvant chemotherapy for cancer patients, its concordance data in South Asian populations is lacking. Present study aims assess toxicity profiles and this cohort patients. Patients planned treatment as per regimen from October 2016 August 2022 our institute were ambispectively analysed RTOG grading outcomes. 58 included (Median age 61 years) FIGO stages I (26, 44.8%), II (5, 8.6%) III (27, 46.6%). surgically staged using robotic (33, 56.9%), laparoscopic (9, 15.5%) open (16, 27.6%) methods. 40 (69%) had Type histology, p53 Napsin A positivity was seen 38 3 respectively. IMRT used 44 (79.3%). Acute Toxicity analysis showed that most common complaint during CTRT diarrhoea (38 65.5%) which only 10 Grade 2. 2 hematological GU toxicities noted 0 Regarding chemotherapy; withdrew consent, 14 peripheral neuropathies (3 discontinued treatment) 15 toxicities. No patient stopped CTRT, 4 further 6 required dose reduction. At median followup 24 months, recurred (Isolated paraaortic recurrences 2, distant metastases 13). Medication requiring persisted 11 1 needed surgery bowel obstruction incisional hernia, no late seen. There good tolerance compliance related breaks CTRT. Relapse majorly sites. These findings line PORTEC trial.